Rim Lakhmiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rim Lakhmiri has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Samira Serragui
Mohammed V University
4 shared publications - Pierre Constant Ntoutoume Nzoghe
Mohammed V University
3 shared publications Landry Missounga
University Hospital Center of Libreville
2 shared publicationsSolange Ntsame
University Hospital Center of Libreville
2 shared publicationsSophie Coniquet
University Hospital Center of Libreville
2 shared publicationsYahia Cherrah
Mohammed V University
2 shared publications
Latest Publications
- 21 August 2026
- Published by SAGE Publications in International Journal of Risk & Safety in Medicine
- Vol. 37 (4) , 554-566
Stevens–Johnson Syndrome identified at the University Hospital Center of Libreville, Gabon: Four case reports
Background: Stevens–Johnson Syndrome (SJS) is a rare and severe drug-induced cutaneous reaction. However, clinical and economic data regarding its management remain poorly documented in Gabon. Therefore, this study aimed to describe the clinical characteristics, drug causality assessment, therapeutic management, and direct medical costs of four confirmed cases of SJS managed at the Libreville University Hospital Center (CHUL). Case report: Four confirmed cases of SJS related respectively to lidocaine, allopurinol, amoxicillin/clavulanic acid, and flucloxacillin were identified. Drug causality assessment, performed using the French causality assessment method, the World Health Organization (WHO) scale, and the ALDEN algorithm, indicated a probable causal relationship in all cases. SCORTEN scores ranged from 0 to 1, corresponding to an estimated mortality rate of 3.2%. Therapeutic management was based on symptomatic and supportive treatment, including Polaramine, Solumedrol, Dacryoserum, eosin solution, Fucithalmic, sodium bicarbonate, Fungizone, Dexeryl, ciprofloxacin, and Exomuc, with favorable clinical outcomes observed in all patients. The mean direct medical cost of management was estimated at 225,089 CFA francs (343.14 €), with a total cost of 860,355 CFA francs (1311.60 €) for the four cases. Conclusion: SJS remains a severe dermatological emergency associated with substantial management costs despite favorable clinical outcomes. These findings highlight the importance of strengthening pharmacovigilance activities and the prevention of serious adverse drug reactions.
- 21 August 2026
- Published by SAGE Publications in International Journal of Risk & Safety in Medicine
- Vol. 37 (4) , 554-566
Stevens–Johnson Syndrome identified at the University Hospital Center of Libreville, Gabon: Four case reports
Background: Stevens–Johnson Syndrome (SJS) is a rare and severe drug-induced cutaneous reaction. However, clinical and economic data regarding its management remain poorly documented in Gabon. Therefore, this study aimed to describe the clinical characteristics, drug causality assessment, therapeutic management, and direct medical costs of four confirmed cases of SJS managed at the Libreville University Hospital Center (CHUL). Case report: Four confirmed cases of SJS related respectively to lidocaine, allopurinol, amoxicillin/clavulanic acid, and flucloxacillin were identified. Drug causality assessment, performed using the French causality assessment method, the World Health Organization (WHO) scale, and the ALDEN algorithm, indicated a probable causal relationship in all cases. SCORTEN scores ranged from 0 to 1, corresponding to an estimated mortality rate of 3.2%. Therapeutic management was based on symptomatic and supportive treatment, including Polaramine, Solumedrol, Dacryoserum, eosin solution, Fucithalmic, sodium bicarbonate, Fungizone, Dexeryl, ciprofloxacin, and Exomuc, with favorable clinical outcomes observed in all patients. The mean direct medical cost of management was estimated at 225,089 CFA francs (343.14 €), with a total cost of 860,355 CFA francs (1311.60 €) for the four cases. Conclusion: SJS remains a severe dermatological emergency associated with substantial management costs despite favorable clinical outcomes. These findings highlight the importance of strengthening pharmacovigilance activities and the prevention of serious adverse drug reactions.
- Open Access
- 16 January 2026
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 5 (1) , 4
Incidence of Adverse Drug Reactions at the University Hospital Center of Libreville, Gabon: From Data Collection to a Risk Minimization Plan
Background: According to the literature, adverse drug reactions (ADRs) account for 5–10% of hospital admissions and affect 25–30% of hospitalized patients, but no data are available for Gabon. Objectives: To estimate the incidence of ADRs among hospitalized patients at the Libreville University Hospital Center (CHUL) and to classify them according to their frequency, severity, mechanism and preventability, while proposing appropriate risk minimization strategies. Patients and Methods: A 14-month, single-center, prospective study included all patients experiencing ADRs, excluding those without ADRs or with intentional overdoses. ADRs were analyzed using the World Health Organization (WHO) causality assessment, the ATC classification, and Rawlins and Thompson criteria. Data were actively collected from patients and hospital records. Results: Among 4999 patients, 105 experienced 177 adverse events (incidence: 3.5%, 95% CI: 1.7–2.5%). Among the identified ADRs, 42% were serious. Nausea and vomiting were the most frequent ADRs, mainly caused by analgesics (nefopam, tramadol) and antibiotics (amoxicillin–clavulanic acid). The gastrointestinal and nervous systems were the most affected. According to the Rawlins and Thompson classification, 90% of ADRs were type A, 8% type B, and 2% type E (withdrawal syndrome). Overall, 90% of ADRs were preventable. Conclusions: This study highlights the importance of pharmacovigilance at CHUL, Gabon, and emphasizes the role of healthcare professionals in ADR reporting and risk minimization.
- 16 January 2026
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 5 (1) , 4
Open AccessIncidence of Adverse Drug Reactions at the University Hospital Center of Libreville, Gabon: From Data Collection to a Risk Minimization Plan
Background: According to the literature, adverse drug reactions (ADRs) account for 5–10% of hospital admissions and affect 25–30% of hospitalized patients, but no data are available for Gabon. Objectives: To estimate the incidence of ADRs among hospitalized patients at the Libreville University Hospital Center (CHUL) and to classify them according to their frequency, severity, mechanism and preventability, while proposing appropriate risk minimization strategies. Patients and Methods: A 14-month, single-center, prospective study included all patients experiencing ADRs, excluding those without ADRs or with intentional overdoses. ADRs were analyzed using the World Health Organization (WHO) causality assessment, the ATC classification, and Rawlins and Thompson criteria. Data were actively collected from patients and hospital records. Results: Among 4999 patients, 105 experienced 177 adverse events (incidence: 3.5%, 95% CI: 1.7–2.5%). Among the identified ADRs, 42% were serious. Nausea and vomiting were the most frequent ADRs, mainly caused by analgesics (nefopam, tramadol) and antibiotics (amoxicillin–clavulanic acid). The gastrointestinal and nervous systems were the most affected. According to the Rawlins and Thompson classification, 90% of ADRs were type A, 8% type B, and 2% type E (withdrawal syndrome). Overall, 90% of ADRs were preventable. Conclusions: This study highlights the importance of pharmacovigilance at CHUL, Gabon, and emphasizes the role of healthcare professionals in ADR reporting and risk minimization.
- 14 March 2025
- Published by SAGE Publications in International Journal of Risk & Safety in Medicine
Fluconazole-induced Stevens-Johnson syndrome at Libreville University Hospital - Gabon: A case report
Background: Stevens-Johnson syndrome (SJS), a rare and severe toxic epidermal necrolysis, is reported here for the first time at the University Hospital Center of Libreville (CHUL), suspected to be related to fluconazole administration. Objective: To inform clinicians about the risks associated with fluconazole in immunocompromised patients and the related healthcare expenses. Case presentation: The patient is a 39-year-old immunocompromised woman who received a single dose 400 mg of fluconazole. Two weeks later, she developed a rash affecting approximately 10 % of her body surface, confirmed as SJS. During clinical examinations, no signs of infection, such as fever, dizziness, or chills, were present, suggesting a drug-induced SJS reaction. Results: Causality assessment assigned an intrinsic score of I6 and extrinsic score of B2 according to the French method, and a probable temporal relationship was confirmed using the world Health Organization (WHO) method. The ALDEN scale identified fluconazole as the probable cause (score = 4). No additional risk factors were identified (SCORTEN = 0, predicted mortality: 3.2 %). Economically, the total direct medical cost of hospitalization amounted to 605,700 CFA francs, or 923.38 €. Conclusion: Immunocompromised HIV-positive patients treated with 400 mg of fluconazole are likely to develop SJS and incur costs.
- 14 March 2025
- Published by SAGE Publications in International Journal of Risk & Safety in Medicine
Fluconazole-induced Stevens-Johnson syndrome at Libreville University Hospital - Gabon: A case report
Background: Stevens-Johnson syndrome (SJS), a rare and severe toxic epidermal necrolysis, is reported here for the first time at the University Hospital Center of Libreville (CHUL), suspected to be related to fluconazole administration. Objective: To inform clinicians about the risks associated with fluconazole in immunocompromised patients and the related healthcare expenses. Case presentation: The patient is a 39-year-old immunocompromised woman who received a single dose 400 mg of fluconazole. Two weeks later, she developed a rash affecting approximately 10 % of her body surface, confirmed as SJS. During clinical examinations, no signs of infection, such as fever, dizziness, or chills, were present, suggesting a drug-induced SJS reaction. Results: Causality assessment assigned an intrinsic score of I6 and extrinsic score of B2 according to the French method, and a probable temporal relationship was confirmed using the world Health Organization (WHO) method. The ALDEN scale identified fluconazole as the probable cause (score = 4). No additional risk factors were identified (SCORTEN = 0, predicted mortality: 3.2 %). Economically, the total direct medical cost of hospitalization amounted to 605,700 CFA francs, or 923.38 €. Conclusion: Immunocompromised HIV-positive patients treated with 400 mg of fluconazole are likely to develop SJS and incur costs.
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 19 (4) , 431-443
Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures
Tumor necrosis factor alpha (TNF- α) inhibitors are widely employed for the management of chronic inflammatory rheumatism. However, their usage carries significant risks, including site and infusion reactions, serious infections, malignancy, heart failure autoimmune and demyelinating disorders. These risks are comprehensively outlined in risk management plans (RMPs) associated with these molecules. RMP provides information on the safety profile of a medicinal product as well as the measures that will be taken to minimize risks; these are known as risk minimization measures. These measures are divided into routine measures related to elements, such as the summary of product characteristics, labeling, pack size, package leaflet, or legal supply status of the product, while additional measures may include educational programs, including tools for healthcare providers and patients, controlled access or pregnancy prevention programs, among others. Additional measures can consist of one or more interventions that need to be implemented in a sustainable way in a defined target group, while respecting the timing and frequency of any intervention and procedures to reach the target population. An evaluation of the effectiveness of these measures is required to determine whether or not an intervention has been effective. This comprehensive review offers an in-depth exploration of the current treatment, uses, and associated risks of TNF-α inhibitors. Additionally, it provides a detailed account of risk minimization measures and risk management practices while shedding light on their real-world implementation and effectiveness.
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 19 (4) , 431-443
Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures
Tumor necrosis factor alpha (TNF- α) inhibitors are widely employed for the management of chronic inflammatory rheumatism. However, their usage carries significant risks, including site and infusion reactions, serious infections, malignancy, heart failure autoimmune and demyelinating disorders. These risks are comprehensively outlined in risk management plans (RMPs) associated with these molecules. RMP provides information on the safety profile of a medicinal product as well as the measures that will be taken to minimize risks; these are known as risk minimization measures. These measures are divided into routine measures related to elements, such as the summary of product characteristics, labeling, pack size, package leaflet, or legal supply status of the product, while additional measures may include educational programs, including tools for healthcare providers and patients, controlled access or pregnancy prevention programs, among others. Additional measures can consist of one or more interventions that need to be implemented in a sustainable way in a defined target group, while respecting the timing and frequency of any intervention and procedures to reach the target population. An evaluation of the effectiveness of these measures is required to determine whether or not an intervention has been effective. This comprehensive review offers an in-depth exploration of the current treatment, uses, and associated risks of TNF-α inhibitors. Additionally, it provides a detailed account of risk minimization measures and risk management practices while shedding light on their real-world implementation and effectiveness.